259 related articles for article (PubMed ID: 19188071)
1. 64Cu-AMD3100--a novel imaging agent for targeting chemokine receptor CXCR4.
Jacobson O; Weiss ID; Szajek L; Farber JM; Kiesewetter DO
Bioorg Med Chem; 2009 Feb; 17(4):1486-93. PubMed ID: 19188071
[TBL] [Abstract][Full Text] [Related]
2. Positron emission tomography imaging of tumors expressing the human chemokine receptor CXCR4 in mice with the use of 64Cu-AMD3100.
Weiss ID; Jacobson O; Kiesewetter DO; Jacobus JP; Szajek LP; Chen X; Farber JM
Mol Imaging Biol; 2012 Feb; 14(1):106-14. PubMed ID: 21347799
[TBL] [Abstract][Full Text] [Related]
3.
Burke BP; Miranda CS; Lee RE; Renard I; Nigam S; Clemente GS; D'Huys T; Ruest T; Domarkas J; Thompson JA; Hubin TJ; Schols D; Cawthorne CJ; Archibald SJ
J Nucl Med; 2020 Jan; 61(1):123-128. PubMed ID: 31201250
[TBL] [Abstract][Full Text] [Related]
4. CXCR4-targeted PET imaging using
Muz B; Bandara N; Mpoy C; Sun J; Alhallak K; Azab F; Rogers BE; Azab AK
Cancer Biol Ther; 2020; 21(1):52-60. PubMed ID: 31571524
[No Abstract] [Full Text] [Related]
5. New AMD3100 derivatives for CXCR4 chemokine receptor targeted molecular imaging studies: synthesis, anti-HIV-1 evaluation and binding affinities.
Poty S; Désogère P; Goze C; Boschetti F; D'huys T; Schols D; Cawthorne C; Archibald SJ; Maëcke HR; Denat F
Dalton Trans; 2015 Mar; 44(11):5004-16. PubMed ID: 25640878
[TBL] [Abstract][Full Text] [Related]
6. [⁹⁹mTc]O₂-AMD3100 as a SPECT tracer for CXCR4 receptor imaging.
Hartimath SV; Domanska UM; Walenkamp AM; Rudi A J O D; de Vries EF
Nucl Med Biol; 2013 May; 40(4):507-17. PubMed ID: 23522974
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4.
Fricker SP; Anastassov V; Cox J; Darkes MC; Grujic O; Idzan SR; Labrecque J; Lau G; Mosi RM; Nelson KL; Qin L; Santucci Z; Wong RS
Biochem Pharmacol; 2006 Aug; 72(5):588-96. PubMed ID: 16815309
[TBL] [Abstract][Full Text] [Related]
8. Molecular imaging of CXCR4 receptor expression in human cancer xenografts with [64Cu]AMD3100 positron emission tomography.
Nimmagadda S; Pullambhatla M; Stone K; Green G; Bhujwalla ZM; Pomper MG
Cancer Res; 2010 May; 70(10):3935-44. PubMed ID: 20460522
[TBL] [Abstract][Full Text] [Related]
9. AMD3100 inhibits epithelial-mesenchymal transition, cell invasion, and metastasis in the liver and the lung through blocking the SDF-1α/CXCR4 signaling pathway in prostate cancer.
Zhu WB; Zhao ZF; Zhou X
J Cell Physiol; 2019 Jul; 234(7):11746-11759. PubMed ID: 30537000
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a fluorescent derivative of AMD3100 and its interaction with the CXCR4 chemokine receptor.
Knight JC; Hallett AJ; Brancale A; Paisey SJ; Clarkson RW; Edwards PG
Chembiochem; 2011 Nov; 12(17):2692-8. PubMed ID: 21998043
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Evaluation of [
Peng T; Wang X; Li Z; Bi L; Gao J; Yang M; Wang Y; Yao X; Shan H; Jin H
Mol Pharm; 2021 Sep; 18(9):3638-3648. PubMed ID: 34424706
[TBL] [Abstract][Full Text] [Related]
12. AMD3100: A Versatile Platform for CXCR4 Targeting (68)Ga-Based Radiopharmaceuticals.
Poty S; Gourni E; Désogère P; Boschetti F; Goze C; Maecke HR; Denat F
Bioconjug Chem; 2016 Mar; 27(3):752-61. PubMed ID: 26886512
[TBL] [Abstract][Full Text] [Related]
13. Comparison of cell-based assays for the identification and evaluation of competitive CXCR4 inhibitors.
Van Hout A; D'huys T; Oeyen M; Schols D; Van Loy T
PLoS One; 2017; 12(4):e0176057. PubMed ID: 28410420
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of SDF-1/CXCR4-induced Ca2+ signaling by fluorometric imaging plate reader (FLIPR) and flow cytometry.
Princen K; Hatse S; Vermeire K; De Clercq E; Schols D
Cytometry A; 2003 Jan; 51(1):35-45. PubMed ID: 12500303
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor: transfer of binding site to the CXCR3 receptor.
Rosenkilde MM; Gerlach LO; Jakobsen JS; Skerlj RT; Bridger GJ; Schwartz TW
J Biol Chem; 2004 Jan; 279(4):3033-41. PubMed ID: 14585837
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the SDF-1alpha-CXCR4 axis by the CXCR4 antagonist AMD3100 suppresses the migration of cultured cells from ATL patients and murine lymphoblastoid cells from HTLV-I Tax transgenic mice.
Kawaguchi A; Orba Y; Kimura T; Iha H; Ogata M; Tsuji T; Ainai A; Sata T; Okamoto T; Hall WW; Sawa H; Hasegawa H
Blood; 2009 Oct; 114(14):2961-8. PubMed ID: 19657116
[TBL] [Abstract][Full Text] [Related]
17. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4.
Hatse S; Princen K; Bridger G; De Clercq E; Schols D
FEBS Lett; 2002 Sep; 527(1-3):255-62. PubMed ID: 12220670
[TBL] [Abstract][Full Text] [Related]
18. CXCR4 antagonist delivery on decellularized skin scaffold facilitates impaired wound healing in diabetic mice by increasing expression of SDF-1 and enhancing migration of CXCR4-positive cells.
Liu H; Liu H; Deng X; Chen M; Han X; Yan W; Wang N
Wound Repair Regen; 2017 Aug; 25(4):652-664. PubMed ID: 28783870
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologically antagonizing the CXCR4-CXCL12 chemokine pathway with AMD3100 inhibits sunlight-induced skin cancer.
Sarchio SNE; Scolyer RA; Beaugie C; McDonald D; Marsh-Wakefield F; Halliday GM; Byrne SN
J Invest Dermatol; 2014 Apr; 134(4):1091-1100. PubMed ID: 24226205
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]